Literature DB >> 28214826

Emodin Increases Expression of Insulin-Like Growth Factor Binding Protein 1 through Activation of MEK/ERK/AMPKα and Interaction of PPARγ and Sp1 in Lung Cancer.

Qing Tang, JingJing Wu, Fang Zheng, Swei Sunny Hann, YuQing Chen.   

Abstract

BACKGROUND: Emodin has anti-neoplastic activities on multiple tumors. However, the molecular mechanisms underlying this effect still remain to be fully understood.
METHODS: Cell viability and cell cycle distribution were measured using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays and flow cytometry, respectively. Cell invasion and migration were examined by transwell invasion and wound healing assays. Western blot analysis was performed to examine the phosphorylation and protein expression of AMP-activated protein kinase alpha (AMPKα), extracellular signaling-regulated kinase 1/2 (ERK1/2), peroxisome proliferators-activated receptor gamma (PPARγ), insulin-like growth factor (IGF) binding protein 1 (IGFBP1) and the transcription factor Sp1. QRT-PCR was used to examine the mRNA levels of the IGFBP1 gene. Small interfering RNAs (siRNAs) were used to knockdown PPARγ and IGFBP1 genes. Exogenously expression of IGFBP1 and Sp1 was determined by transient transfection assays. IGFBP1 promoter activity was measured by Secrete-Pair Dual Luminescence Assay Kit. In vivo nude mice xenograft model and bioluminescent imaging system were used to confirm the findings.
RESULTS: We showed that emodin induced cell cycle arrest of NSCLC cells. Emodin increased PPARγ protein and luciferase reporter activity, which were abolished by inhibitors of MAPK extracellular signaling-regulated kinase (ERK) kinase (MEK)/ERK and AMPK. Silencing of PPARγ abrogated emodin-inhibited cell growth and cell cycle arrest. Furthermore, emodin elevated IGFBP1 mRNA, protein, and promoter activity through activation of PPARγ. Intriguingly, overexpressed Sp1 attenuated emodin-induced IGFBP1 expression, which was not observed in cells with silenced PPARγ gene. Moreover, silencing of IGFBP1 gene blunted emodin-induced inhibition of cell growth and cell cycle arrest. On the contrary, overexpressed IGFBP1 enhanced emodin-induced phosphorylation of AMPKα and ERK1/2, and restored emodin-inhibited growth in cells with silenced endogenous IGFBP1 gene. Emodin also inhibited growth of lung xenograft tumors and Sp1, and increased IGFBP1 and PPARγ protein expressions In vivo.
CONCLUSION: Collectively, our results show that emodin inhibits growth of non-small-cell lung cancer (NSCLC) cells through ERK and AMPKα-mediated induction of PPARγ, followed by reduction of Sp1. This in turn induces IGFBP1 gene expression. Thus, the signaling cascades, positive feedback loop and cooperative interplay between transcription factors-induced the expression of IGFBP1 gene contribute to the overall responses of emodin. This study provides a novel mechanism by which emodin inhibits growth of human lung cancer cells.
© 2017 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Emodin; IGFBP1; NSCLC; PPARγ; Sp1

Mesh:

Substances:

Year:  2017        PMID: 28214826     DOI: 10.1159/000456281

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  10 in total

Review 1.  The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.

Authors:  Qing Zhang; Wen Wen Chen; Xue Sun; Die Qian; Dan Dan Tang; Li Lin Zhang; Mei Yan Li; Lin Yu Wang; Chun-Jie Wu; Wei Peng
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

2.  Tescalcin promotes highly invasive papillary thyroid microcarcinoma by regulating FOS/ERK signaling pathway.

Authors:  Xiuhe Zou; Qian Zhou; Yan Nie; Junhe Gou; Jing Yang; Jingqiang Zhu; Zhihui Li; Yanping Gong
Journal:  BMC Cancer       Date:  2022-05-31       Impact factor: 4.638

Review 3.  Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin.

Authors:  Esra Küpeli Akkol; Iffet Irem Tatlı; Gökçe Şeker Karatoprak; Osman Tuncay Ağar; Çiğdem Yücel; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

4.  Emodin Inhibits EBV Reactivation and Represses NPC Tumorigenesis.

Authors:  Chung-Chun Wu; Mei-Shu Chen; Yu-Jhen Cheng; Ying-Chieh Ko; Su-Fang Lin; Ing-Ming Chiu; Jen-Yang Chen
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

5.  Neuroprotective Effects of Emodin against Ischemia/Reperfusion Injury through Activating ERK-1/2 Signaling Pathway.

Authors:  Stephen Wan Leung; Jing Huei Lai; John Chung-Che Wu; Yan-Rou Tsai; Yen-Hua Chen; Shuo-Jhen Kang; Yung-Hsiao Chiang; Cheng-Fu Chang; Kai-Yun Chen
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

Review 6.  ERK/MAPK signalling pathway and tumorigenesis.

Authors:  Yan-Jun Guo; Wei-Wei Pan; Sheng-Bing Liu; Zhong-Fei Shen; Ying Xu; Ling-Ling Hu
Journal:  Exp Ther Med       Date:  2020-01-15       Impact factor: 2.447

7.  Safety of natural anthraquinone emodin: an assessment in mice.

Authors:  Alexander T Sougiannis; Reilly T Enos; Brandon N VanderVeen; Kandy T Velazquez; Brittany Kelly; Sierra McDonald; William Cotham; Ioulia Chatzistamou; Mitzi Nagarkatti; Daping Fan; E Angela Murphy
Journal:  BMC Pharmacol Toxicol       Date:  2021-01-28       Impact factor: 2.483

8.  Inactivation of Stat3 and crosstalk of miRNA155-5p and FOXO3a contribute to the induction of IGFBP1 expression by beta-elemene in human lung cancer.

Authors:  Fang Zheng; Qing Tang; Xiao-Hua Zheng; JingJing Wu; HaiDing Huang; Haibo Zhang; Swei Sunny Hann
Journal:  Exp Mol Med       Date:  2018-09-12       Impact factor: 8.718

Review 9.  Quinonoids: Therapeutic Potential for Lung Cancer Treatment.

Authors:  Hua-Zhong Ying; Chen-Huan Yu; Hao-Kun Chen; Huan-Huan Zhang; Jie Fang; Fang Wu; Wen-Ying Yu
Journal:  Biomed Res Int       Date:  2020-04-06       Impact factor: 3.411

10.  Emodin inhibits viability, proliferation and promotes apoptosis of hypoxic human pulmonary artery smooth muscle cells via targeting miR-244-5p/DEGS1 axis.

Authors:  Li Yi; JunFang Liu; Ming Deng; Huihua Zuo; Mingyan Li
Journal:  BMC Pulm Med       Date:  2021-07-31       Impact factor: 3.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.